Studies on the Syntheses of Spiro-dienone Compounds. V. An Improved Synthetic Method of Spiro-dienone Compounds. Syntheses of dl-Mecambrine, dl-Amurine and dl-Domesticine
The present invention aims to provide an iminopyridine derivative compound having an α
1D
adrenergic receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like.
The present invention provides a compound represented by the formula
wherein each symbol is as defined in the specification, or a salt thereof.
Acid (conc. H2SO4-Ac2O) treatment of the p-quinol acetate derived from (±)-1, 2, 3, 4-tetrahydro-7-hydroxy-6-methoxy-2-methyl-1-(3', 4'-methylenedioxy-benzyl or -phenethyl)-isoquinoline (VIII or IX) gave the corresponding 1-monoacetoxy-and 1, 4-diacetoxy-aporphine (XIX, XXa, and XXb) or-homoaporphine (XXIII and XXIV), respectively. Hydrolysis of XIX afforded (±)-domesticine (VI).
[EN] CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR<br/>[FR] MODULATEURS CYCLOPROPYLÉS DU RÉCEPTEUR P2Y12
申请人:AUSPEX PHARMACEUTICALS INC
公开号:WO2011017108A2
公开(公告)日:2011-02-10
The present invention relates to new cyclopropyl modulators of P2Y12 receptor activity, pharmaceutical compositions thereof, and methods of use thereof.
本发明涉及新的环丙基P2Y12受体调节剂,其制药组合物以及使用方法。
CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR
申请人:Auspex Pharmaceuticals, Inc.
公开号:US20160193212A1
公开(公告)日:2016-07-07
The present invention relates to new cyclopropyl modulators of P2Y12 receptor activity, pharmaceutical compositions thereof, and methods of use thereof.
本发明涉及P2Y12受体活性的新环丙基调节剂,其制药组合物以及使用方法。
IMINOPYRIDINE DERIVATIVE AND USE THEREOF
申请人:Takeda Pharmaceutical Company Limited
公开号:EP2077262A1
公开(公告)日:2009-07-08
Provided are an iminopyridine derivative having a selective α1D adrenergic receptor antagonistic action and useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like, and a screening method for a compound having an α1D adrenergic receptor antagonistic action. An α1D adrenergic receptor antagonist containing a compound represented by the formula:
wherein each symbol is as defined in the specification, or a salt thereof, and a method of screening for an agent having an α1D adrenergic receptor antagonistic action for the prophylaxis or treatment of a lower urinary tract disease, which includes measuring the bladder smooth muscle tension of rats with bladder outlet obstruction.